4 results
Primary objectives:• To evaluate the safety and tolerability of BMS-914143 as measured by the frequency of SAEs and discontinuations due to AEs;• To assess the HBeAg seroconversion rate at 24 weeks off treatment (Week 72).Secondary objective• To…
The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.
Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease
Primary objective: determining the effect of the ketohexokinase inhibitor, PF-06835919, on hepatic insulin sensitivity in individuals with non-alcoholic fatty liver disease.Secondary objective: determining the effect of the ketohexokinase inhibitor…